Clinical Trials Logo
  1. Home
  2. Relapsing Multiple Sclerosis
  3. NCT02921035

Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

Relapsing Multiple Sclerosis (RMS) Clinical Trial

Official title:
A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With RMS Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a (MAIN-MS)

Clinical Trial Summary

This is an open label, non randomized, uncontrolled, multicenter, single arm observational study. In this study, the enrolled subjects will be treated with Rebif human serum albumin (HSA)-free formulation (with or without RebiSmart) 44 microgram (mcg), subcutaneous (sc), thrice in a week (tiw) for 24 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02921035
Study type Observational
Source Merck KGaA, Darmstadt, Germany
Contact
Status Completed
Phase
Start date June 30, 2016
Completion date July 27, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT03277261 - Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) Phase 3
Active, not recruiting NCT04130997 - An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis Phase 3
Completed NCT04878211 - A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab Phase 4
Recruiting NCT04086225 - Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon® Phase 1
Completed NCT03745144 - Effects of Cladribine Tablets on the PK of Microgynon® Phase 1
Active, not recruiting NCT04667949 - Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients Phase 4
Completed NCT03277248 - Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) Phase 3